NFATC1 and vitiligo: reported that Tregs from patients with vitiligo of early onset (≤ 20 years) showed lower activities to suppress proliferation of CD8+ or CD4+ T cells and reduced expression of transforming growth factor β and nuclear factor of activated T cells 1, compared with patients with later‐onset vitiligo (> 40 years).33